Intravenous vs intrathecal transplantation of allogeneic GMP/GCP compliant Wharton’s jelly mesenchymal stromal cells in ALS patients: a phase I study

Introduction There are a few therapeutic approaches for Amyotrophic Lateral Sclerosis (ALS) which can only slow down or stop the disease progression for a limited period of time. Since it has been proven that Mesenchymal Stromal Cells (MSCs) produce neurotrophic factors and have some neuroprotective effects, stem cell therapy has been proposed as an alternative or add-on treatment for ALS patients.